Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...
With many patients utilizing medical cannabis, it is important for nurses to be aware of potential drug-drug interactions, an expert said.
A nurse practitioner discusses how breast cancer treatment can impact sexual health, and how nurses and APPs can guide ...
An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...
The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of ...
With newer breast cancer treatments, it’s essential that nurses and APPs educate themselves and advocate for their patients.
Nurse navigators and APPs are key members of the multidisciplinary team who can lead and implement QI efforts to ensure timely and effective biomarker testing for patients with early-stage NSCLC.
October 2024 brought 4 new FDA drug approvals in the oncology space. With new drug regimens in both the solid tumor and blood ...
The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.
The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The FDA has approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback